Purpose Translocator protein (TSPO) is a promising biomarker for neuroinflammation. We developed two new PET ligands, 18
Introduction
Translocator protein 1 (18 kDa) (TSPO) is upregulated on activated microglia and is therefore a biomarker for inflammation [2] . For the past two decades, TSPO has been imaged using the positron emission tomographic (PET) ligand 11 C-PK11195, but in the last several years, a number of improved PET ligands with higher ratios of specific to nondisplaceable binding have been developed from new structural classes [3] . We developed two new aryloxyanilide-based ligands, 18 F-PBR06 [4] and 11 C-PBR28 [5] , to image TSPO (Fig. 1) . In monkey brain, the specific binding of each ligand was greater than 90% of its total uptake [6, 7] .
In human brain, both ligands precisely quantified TSPOs as distribution volumes using compartmental modeling [8, 9] . However, the distribution volumes of both ligands increased with longer duration of data, compatible with the accumulation of radiolabeled metabolites over time. Across brain regions, distribution volumes of 18 F-PBR06 had somewhat better identifiability than those of 11 C-PBR28. 1 Translocator protein was formerly named peripheral benzodiazepine receptor (PBR) because it was originally found as a binding site for diazepam in peripheral organs. To reflect its distribution in both central nervous system and peripheral organs and also to reflect its functions, PBR has been renamed as translocator protein [1] .
These prior findings raise the possibility that 18 F-PBR06 may quantify TSPOs more precisely than 11 C-PBR28, particularly in small brain regions; however, this conclusion is uncertain, since the two radioligands were studied in different subjects.
PBR06 and PBR28 differ in terms of lipophilicity and in vitro affinity for TSPO, and both properties can significantly affect in vivo binding of the cognate radioligands. The lipophilicity of PBR06 is about ten times greater than that of PBR28: log D=4.l vs 3.0, respectively, measured in octanol/phosphate buffer, pH 7.4 [4, 5] . Although increasing lipophilicity enhances blood-brain barrier penetration, it also tends to increase nondisplaceable uptake in brain, which has a high content of fat.
The in vitro assays performed in our lab showed that PBR06 had slightly but significantly greater affinity for TSPO than PBR28 in human brain tissue (K i =1.0 vs 2.5 nM, respectively) [4, 5] . If the same relationship holds also in vivo, 18 F-PBR06 would be expected to have higher specific binding to TSPO than 11 C-PBR28. Since total distribution volume (V T ) is the sum of specific (V S ) and nondisplaceable (V ND ) distribution volumes, the higher lipophilicity and higher in vitro affinity of PBR06 compared to PBR28 suggests that the V T of 18 F-PBR06 will be greater than that of 11 C-PBR28. However, because the in vivo environment can differ markedly from in vitro conditions, PET measurements may not reflect in vitro properties.
In this study, we compared 18 F-PBR06 and 11 C-PBR28 in the same healthy subjects to determine (1) whether either ligand provides more precise measurements, as indirectly measured as identifiability of distribution volume, and (2) whether 18 F-PBR06 and 11 C-PBR28 show different amounts of in vivo binding. To answer these questions, we scanned eight healthy subjects with both ligands and analyzed the same length of the data using compartmental modeling with metabolite-corrected arterial input function.
Materials and methods
Eight healthy subjects (two women and six men; age 32± 11 years) had PET scans with both 18 F-PBR06 and 11 C-PBR28. The mean interval between the two scans was 7.6 months (range 2-21 months). Data from all eight 18 F-PBR06 scans and from three 11 C-PBR28 scans were included in previous publications, where detailed descriptions of data acquisition and analyses are provided [8, 9] .
18 F-PBR06 and 11 C-PBR28 were produced with high radiochemical purity (100%) and had specific radioactivities of 246±93 and 100±45 GBq/μmol, respectively, at the time of injection. After a bolus intravenous injection of 18 F-PBR06 (170±26 MBq) or 11 C-PBR28 (567±84 MBq), dynamic PET scans were acquired on a GE Advance scanner (GE Healthcare, Waukesha, WI, USA). Concurrent blood samples were drawn from the radial artery, and the plasma concentration of parent radioligand, separated from its radiometabolites by radio-HPLC, was measured to generate a metabolite-corrected input function for kinetic modeling. In addition, plasma free fraction (f P ) was measured in each scan. From the dynamic PET scans, we measured radioactivity in ten brain regions (anterior cingulate, cerebellum, caudate, putamen, thalamus, and frontal, parietal, temporal, occipital, and medial temporal cortices) [9] . Radioactivity concentrations in both brain and plasma were decay-corrected and expressed as standardized uptake values (SUVs) to normalize for injected activity and body weight.
TSPO binding was measured as V T normalized to f P , which equals the ratio at equilibrium of radioactivity in brain to the concentration of free (i.e., non-protein-bound) parent radioligand in plasma [10] . V T was first calculated using an unconstrained two-tissue compartment model and metabolite-corrected input function [8, 9] and then normalized to f P . Identifiability (SE) of V T , an indicator of precision, was expressed as a percentage of V T itself, with a lower percentage corresponding to better identifiability. Data were acquired for 300 and 120 min for 18 F-PBR06 and 11 C-PBR28, respectively. In the current study, the same length of 120 min data were used for both ligands to allow direct comparison. Furthermore, in our prior study with 18 F-PBR06 data acquired over 120 min provided the most accurate and precise measurement based on the time stability and the best identifiability [8] . Because only free ligand can enter the brain, we calculated V T /f P as our primary outcome measure of ligand binding. Analyses were performed using pixelwise modeling software (PMOD 2.85, PMOD Technologies Ltd., Zurich, Switzerland) and Statistical Parametric Mapping 5 (SPM 5, Wellcome Department of Cognitive Neurology, London, UK).
We compared V T /f P measurements by the two ligands to determine whether the measurements had similar precision and were consistent. First, we compared the precision of binding measurements in terms of identifiability of V T . We considered V T values with SE≤10% to be well identified. Second, we examined the time stability of V T by truncating PET data in 10-min increments until the scan length reached 30 min and then normalizing V T to the terminal value at 120 min. To further study the precision of the measurements by the two ligands, we examined the correlation between V T /f P values in ten brain regions. Because the two ligands bind to the same molecule, if errors in the measurement of each ligand are small, V T /f P values should correlate well between the two ligands. In addition to examining precision and consistency of the measurements, we compared the in vivo affinities (1/K D ) of the ligands using the regional differences in V T / f P values in analogy to the Lassen plot [11] . A ratio of the in vivo affinities of the two ligands was obtained from the slope of a regression line fitted to V T /f P values in ten brain regions by making two assumptions. The first assumption was that the V ND (free plus nonspecific) of both ligands is uniform across brain regions, because our monkey scans under binding blockade showed uniform distribution of activity [6, 7] . Consequently, because V T /f P is a summation of V S and V ND (V S /f P and V ND /f P , respectively) the difference in V T /f P between any two brain regions corresponds to the difference in V S /f P . The second assumption was that both ligands have the same receptor density (B max ), since they are expected to bind to the identical target site given their structural similarity. It then follows from the equation V S /f P =B max /K D that the ratio of the difference between any two brain regions in V T /f P of 18 F-PBR06 to that of 11 C-PBR28 (i.e., the slope of the regression line) corresponds to a ratio of the affinity of 11 C-PBR28 to that of 18 F-PBR06 because the regional differences of B max between the two ligands cancel out.
Data are expressed as mean ± SD. Brain data are reported as the mean of ten brain regions, each averaged across eight subjects. For statistical comparisons of 18 F-PBR06 and 11 C-PBR28, we used a paired samples t test to compare f P and repeated measures analysis of variance (ANOVA) to compare V T , V T /f P , identifiability, and time stability.
Results

Kinetics in plasma and brain
18 F-PBR06 and 11 C-PBR28 showed overall similar plasma total (= free plus protein-bound) parent levels, but the C-PBR28 were similar in the first 15 min after injection: concentrations peaked within 2 min and then rapidly declined (Fig. 2a) . After the first 15 min, 18 F-PBR06 was cleared from plasma more slowly than 11 C-PBR28 (p<0.05; Fig. 2b ). Brain uptake of radioactivity peaked within 5 min of injection for both ligands and then declined for the remainder of the scan (Fig. 3) . Table 1 ). However, the f P of 18 F-PBR06 was also only half that of 11 C-PBR28 (2.2±0.6 vs 4.4± 1.1%, p<0.001). Despite the twofold difference in V T , V T /f P , the primary measure of ligand binding, did not differ between 18 F-PBR06 and 11 C-PBR28 (100.7±24.0 vs 96.8± 16.7, p=0.75; Table 1 ). In other words, after normalizing V T to f P to reflect only free ligand available to bind to receptors, 18 F-PBR06 and 11 C-PBR28 showed similar binding levels. Not only was the mean value of binding (V T /f P ) in brain similar for both radioligands, the relative regional distribution was also quite similar. V T /f P values of 18 F-PBR06 in ten brain regions correlated closely with those of 11 C-PBR28 (r=0.92, p<0.0005), indicating that the measurements were consistent and did not contain large errors to make the correlation nonsignificant.
We also compared 18 F-PBR06 and 11 C-PBR28 with regard to precision of measuring V T and the time stability of V T . Both 18 F-PBR06 (SE 3%, mean of ten regions in eight subjects) and 11 C-PBR28 (SE 5%) identified V T well in all Data are means ± SD in eight subjects (Table 2) , and we did not find a clear difference between the two ligands in identifiability of V T (p=0.36 by repeated measures ANOVA). Similarly, the two ligands did not differ with respect to time stability of V T (p=0.12 by repeated measures ANOVA), though V T of both ligands increased as scan duration increased (Fig. 4) .
Based on the slope of the regression line (Fig. 5) , we also compared the in vivo affinities (1/K D ) of the two ligands. The slope, which equals the ratio of the affinity of 18 F-PBR06 to that of 11 C-PBR28, was 1.37 and did not significantly deviate from unity (95% confidence interval 0.89-1.84). The y-intercept was −32.
Discussion
The present comparison of 18 F-PBR06 and 11 C-PBR28 in vivo in human brain shows that these two ligands provide similarly precise measurements of TSPOs (measured as the identifiability in compartmental analysis), similar amounts of total brain uptake after correction of f P , and similar regional distribution in brain. With regard to precision, although in our prior studies 18 F-PBR06 had somewhat better identifiability than 11 C-PBR28, when we studied these two ligands in the same subjects, we did not find a significant difference in the identifiability of V T across brain regions. Consistent with our prior studies, both ligands identified V T well (SE≤10%). Also consistent with prior findings, both ligands suffered from relatively poor time stability, as V T increased with scan duration, which is compatible with accumulation of radiolabel in the brain. However, the time dependence of V T was not significantly different between the two ligands.
We predicted that 18 F-PBR06 would have higher total brain uptake than 11 C-PBR28, because PBR06 has almost tenfold higher lipophilicity (which tends to increase nonspecific binding) and 2.5-fold higher in vitro affinity (which increases specific binding). In fact, total brain uptake corrected for plasma protein binding (V T /f P ) was very similar for both radioligands. Please note that correction for plasma protein binding is important for a valid comparison. That is, higher lipophilicity and affinity imply higher nonspecific and specific binding, respectively, at equilibrium and in relation to the equilibrium concentration of free radioligand in plasma or brain. This failed prediction demonstrates that in vitro properties do not directly correlate with in vivo performance. Furthermore, we could estimate the in vivo affinity of the radioligands using a modification of the Lassen plot [11] . The slopes of linear regression of V T /f P values showed that two ligands had similar in vivo affinities, contrary to the higher in vitro affinity of 18 F-PBR06 relative to that of 11 C-PBR28. Although not studied as part of this paper, both 18 F-PBR06 and 11 C-PBR28 are probably sensitive to variable affinity states of TSPO. We initially discovered the lowaffinity state using 11 C-PBR28 in healthy subjects whose images suggested they had essentially no specific binding in brain or in peripheral organs. We found that about 10% of the population (11 subjects of ∼120 scanned to date) appeared to be non-binders. In vitro receptor binding to membranes of white blood cells showed that non-binders do have TSPOs, but their affinity for PBR28 was about 50-fold lower than that in the majority (90%) of the population. Owen and colleagues [12] found this low-affinity state directly in postmortem brain of ∼20% of subjects. They also found that ∼30% of subjects had mixed affinity, consistent with about half of all TSPOs in the highaffinity state and half in the low-affinity state. Since discovering the low-affinity state ("non-binders") with PET using 11 C-PBR28, we then excluded such subjects from scans using 18 F-PBR06. We excluded subjects based on whole-body imaging using 11 C-PBR28. Although we have not directly identified a subject with low-affinity TSPOs using 18 F-PBR06 PET imaging, we think that subjects with low affinity for PBR28 will also show low affinity for PBR06. Preliminary results from Owen and colleagues (personal communication) using postmortem human brain shows that PBR06 is sensitive to high-and low-affinity states but to a lesser degree than PBR28. In patients with neuroinflammation, both 18 F-PBR06 and 11 C-PBR28 are expected to detect an increase in TSPO expression with similar magnitude and precision based on the current study in healthy humans. However, under the circumstances where the levels of specific binding are markedly higher than those in normal tissue, it is possible that these two ligands reveal small differences.
Conclusions
Because the present study of 18 F-PBR06 and 11 C-PBR28 did not reveal notable differences in their quantification of TSPOs, the major point of consideration for selecting one of the two ligands derives from its radionuclide.
11
C-PBR28 offers the advantages of nearly threefold lower radiation exposure than 18 F-PBR06, with effective doses of 6.6 and 18.5 μSv/MBq, respectively [13, 14] . On the other hand, because 18 F-PBR06 has a longer half-life (110 min) than 11 C-PBR28 (20 min), it can be produced at a more distant cyclotron and then transported to other facilities. Thus, 18 F-PBR06 has greater potential than 11 C-PBR28 for widespread clinical use in patients with neuropsychiatric disorders.
